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ABSTRACT 
To compare the bioavailability and bioequivalence of two prasugrel formulations one as a test and the other was the standard. The study was performed 
according to a randomized, open label, balanced, two-treatment, two-period, two-sequence, single-dose, crossover under fasting period with minimum of 
seven days wash-out period and was evaluated in 20(+ 2 stand by) subjects. To analyse pharmacokinetic properties, the blood samples were drawn taken up to 
36 h after dosing. Plasma concentration of prasugrel was determined using liquid chromatography – tandem mass spectrometry method. Pharmacokinetic 
parameters tmax, Cmax, AUC0-t, AUC0-¥, t1/2 and λz (Kel) were tested for bioequivalence after log-transformation of data and non-parametric evaluation 
was done for ratios of tmax. The point estimates and 90 % confidence intervals (CI) for AUC0-t, AUC0-∞, and Cmax for active metabolite (R-138727) were 
95.82-105.18, 96.00-104.69 and 90.80-103.20 respectively. These results indicated that the two formulations of Prasugrel were bioequivalent in case of active 
metabolite (R-138727), thus may be prescribed interchangeably. 
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INTRODUCTION 
Bioavailability,  Systemic  bioavailability,  physiological 
bioavailability,  biological  availability  all  these  terms  are 
interchangeable and denote the measurement of the rate and 
extent (total amount) of the drug that reaches the systemic 
circulation  following  the  administration  of  a  dosage  form. 
Bioavailability means the rate and extent to which the active 
ingredient or active moiety is absorbed from a drug product 
and  becomes  available  at  the  site  of  action.  The 
pharmacokinetic  (Pk)  parameters  by  which  we  can  assess 
bioavailability  are  rate,  tmax,  Cmax,  extent,  AUC. 
Bioequivalence  studies  are  the  preliminary  requirement  for 
generic products to enter in the market. Bioavailability (BA) 
and  Bioequivalence  (BE)  studies  provide  important 
information  in  the  overall  set  of  data  that  ensure  the 
availability  of safe  and effective  medicines to  patients  and 
practitioners.  Prasugrel  is  a  thienopyridine  prodrug  that  is 
metabolized  in  vivo  to  an  adenosine  diphosphate  (ADP) 
receptor  antagonist,  which  is  a  potent  inhibitor  of  ADP-
induced  platelet  aggregation
1-4.  Prasugrel  co  administered 
with  aspirin  is  under  investigation  for  the  prevention  of 
atherothrombotic  events  in  patients  with  acute  coronary 
syndrome
5  (myocardial  infarction  or  unstable  angina)  who 
undergoes  percutaneous  coronary  intervention  (PCI). 
Thienopyridines block the ADP P2Y12 receptor on platelets 
and offer additive effects when given with aspirin because of 
their differing but complementary mechanism of action. Like 
clopidogrel, prasugrel is a thienopyridyl prodrug. The active 
metabolite of prasugrel (R-138727), a sulfhydryl compound, 
binds  covalently  and  irreversibly  to  the  platelet 
P2Y12 receptor  via  a  disulfide  bond.
6 Because  of  this 
irreversible  binding  of  the  active  metabolite,  there  is 
permanent  blockade  of  ADP-mediated  P2Y12 signalling  and 
inhibition of both glycoprotein IIb / IIIa receptor activation 
and  platelet  aggregation.
7  Prasugrel  produces  inhibition 
of platelet aggregation to 20 μM or 5 μM ADP, as measured 
by light transmission aggregometry.
5 Although the activation 
/ metabolism of both prasugrel and clopidogrel involves some 
of the same Cytochrome peroxidase (CYP) enzyme systems 
the potential for pharmacokinetic interactions differs between 
prasugrel and clopidogrel. For example, competition for CYP 
3A4 may explain why the antiplatelet effect of clopidogrel is 
reduced  when  given  concomitantly  with  atorvastatin  or 
dihydropyridine  calcium  channel  blockers  (CCBs). 
Concomitant  administration  of  dihydropyridine  CCBs  and 
clopidogrel  also  increased  the  risk  of  an  adverse 
cardiovascular outcome (adjusted hazard ratio [HR] = 3.5, 95 
% CI = 1.4) Prasugrel is rapidly and extensively metabolized 
to  the  active  metabolite  (R-138727)  and  several  inactive 
metabolites. Metabolism to R-138727 is primarily via CYP 
3A4  and  CYP2B6.  Exposure  to  the  active  metabolite  and 
clinical  outcomes  are  not  affected  by  CYP  2C19  and  2C9 
polymorphism. Rapid conversion of the parent drug to active 
metabolite  (median  time  to  peak  plasma  concentration  is 
approximately  30  minutes.  Dosage:  The  regimen  for 
prasugrel typically used in clinical trials has been a 60-mg 
Loading  dose  (LD)  followed  by  a  10-mg  /  d  maintenance 
dose  (MD)
  8-9.  Median  elimination  half-life  of  the  active 
metabolite  is  approximately  7.4  h.  Excretion  is  primarily 
urinary (approximately 70 %) and faecal excretion is < 30 %. 
Food effect: Fasting administration preferred; Cmax is reduced 
by 49 % and tmax delayed 0.5-1.5 h when administered with 
high-fat high calorie meal, although area under curve (AUC) 
is unaffected. Bioavailability is unaffected by food. 
 
Safety Profile of Prasugrel 
It is not surprising that prasugrel, which has more potent anti 
platelet  effects  than  clopidogrel,  may  cause  increased 
bleeding in clinical use. The phase II PRINCIPLE-TIMI 44 
study  (thombolysis  in  myocardial  infarction),  in  which  the 
primary  end  point  was  anti  platelet  activity,  included  201 
patients undergoing PCI who were randomized to prasugrel 
at  a  loading  dose  of  60  mg  then  14  days  of  maintenance 
therapy with 10 mg per day or clopidogrel 600 mg then 150 
mg  per  day.  After  14  days,  patient  crossed  over  to  the 
alternate anti platelet agent. During the loading dose and pre-Sahu Nimain Charan et al. Int. Res. J. Pharm. 2013, 4 (8) 
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crossover  phase,  19  of  102  (18.6  %)  patients  receiving 
prasugrel and 14 of 99 (14.1 %) randomized to clopidogrel 
had  any  type  of  bleeding  event  (not  significant).  Prior  to 
crossover,  2  patients  (2.0  %)  in  the  prasugrel  group 
experienced  a  thombolysis  in  myocardial  infarction  TIMI 
minor  bleeding  episode  compared  with  no  patients  in  the 
clopidogrel group. After crossover, 4 patients who received 
clopidogrel followed by prasugrel experienced a hemorrhagic 
adverse event (TIMI major or minor bleeding) compared with 
no patients who received prasugrel followed by clopidogrel. 
No TIMI major bleeding events were observed through day 
29 of this study. 
 
Objectives of the Study 
To assess the bioavailability and safety of drug Prasugrel (10 
mg) tablets compare with reference product (10 mg tablets) in 
20 (+ 2 stand by) healthy human adult male subjects under 
fasting condition. 
 
Study Design 
The present study was a randomized, open label, balanced, 
two-treatment, two-period, two-sequence, single-dose, cross 
over under fasting period with minimum of seven days wash-
out period and was evaluated in 20 (+ 2 stand by) subjects. 
 
Inclusion Criteria and Exclusion Criteria 
Healthy human male subjects between 18-45 years weighing 
at least 50 kg and with a body mass index (BMI) of 18.0 kg / 
m
2 and £ 25.0 kg / m
2 were included in the study. Only those 
individuals willing to sign the informed consent form were 
included.  Subjects  were  selected  after  passing  a  clinical 
screening procedure including a physical examination, ECG 
and clinical laboratory tests (hemoglobin, hematocrit, WBC, 
platelets,  WBC  differential,  blood  urea  nitrogen,  sGPT, 
sGOT,  alkaline  phosphatase,  total  bilirubin,  total  protein, 
fasting  glucose,  albumin,  creatinine,  urine  analysis, 
pregnancy test (for female subjects) and negative results of 
HBsAg, anti HBC and anti HIV. Subjects were excluded if 
they  had  a  history  of  any  illness  of  the  hepatic,  renal  and 
cardiovascular system, took alcohol or other medications for 
a long period of time, had hypersensitivity to Prasugrel, had 
received  any  investigation  drug  within  four  weeks  (or 
suitable  longer  period  for  slowly  eliminated  drugs)  of 
enrolment and donation or loss more than 450 ml of blood 
within 3 months prior to the screening of the study. Subjects 
with systolic blood pressure less than 90 mm of Hg and with 
diastolic  blood  pressure  greater  than  140  mm  of  Hg  were 
excluded in the study. 
 
METHODOLOGY 
The  protocol  study  was  approved  by  Drugs  Controller 
General of India and reviewed by Institutional Review Board 
and  Independent  Ethical  Committee.  This  study  was 
conducted  in  compliance  with  the  ethical  principles  of  the 
Declaration  of  Helsinki  for  biomedical  research  involving 
human  volunteers  and  Good  Clinical  Practice  (GCP).  All 
participants signed a written informed consent after they had 
been  informed  of  the  nature  and  details  of  the  study.  The 
study was based on a randomized, open label, balanced, two-
treatment, two-period, two-sequence, single-dose, crossover 
under fasting period with minimum of seven days wash-out 
period was evaluated in 20 (+ 2 stand by) subjects. Subjects 
were randomized to one of the two sequences to receive the 
formulations  according  to  randomization  scheme.  The  test 
preparation was 10 mg of Prasugrel tablets, manufactured by 
Panacea biotec limited and the reference formulation was 10 
mg Effient
® tablets, produced by Eli Lily and Company. The 
sample size n = 20 (+ 2 stand by) subjects was sufficient to 
ensure  power  of  80  %  for  correctly  concluding 
bioequivalence  under  the  following  assumption:  a  =  0.05, 
0.95 < μT / μR < 1.05 and an intra-subject variability of 20 
%.  A  total  of  20  subjects  (males)  were  selected  and 
participated in this study.  The demographic data  of twenty 
volunteers are shown in Table 1. All subjects were avoided 
using other drugs for at least two weeks prior to the study and 
after its completion. They were also refrained from ingesting 
alcohol, caffeine, chocolate, tea or coke containing beverages 
at least 48 h before each dosing and until the collection of the 
last blood sample. Subjects were confined to clinical unit of 
Sipra  Labs  one  night  before  study  to  assure  the  fasting 
condition  (10  h  before  drug  administration).  On  the  study 
day, subjects were given one tablet of either product with 240 
ml  of  water.  No  food  was  allowed  until  4  h  after  dose 
administration. Water intake was allowed 1 h after the dose. 
Standard  meals  were  served  at  4  and  11  h  after  drug 
administration.  Snack  was  served  at  8  h  after  drug 
administration.  Subjects  were  remained  upright  (sitting  or 
standing) for the first 4 h. Subjects were confined at clinical 
unit  of  Sipra  Labs  for  24  h  after  dosing  and  were  not 
permitted  to  take  strenuous  exercise  during  the  sampling 
days.  Blood  pressure,  heart  rate,  body  temperature  and 
adverse events were monitored during blood sampling. 5 ml 
of the venous blood were collected at pre dose, 0.17, 0.33, 
0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00, 
10.00,  12.00,  16.00,  24.00  and  36.00  h  after  drug 
administration  in  the  heparinised  tubes.  After  blood 
separation, plasma was frozen at -20°C until analysis. After 
two weeks wash out period, subjects returned to Sipra Labs 
and  the  blood  sample  analysis  was  repeated  in  the  second 
period in the same manner to complete the crossover design. 
 
Safety Evaluation  
There were no serious adverse events observed in the study. 
 
LC-MS  /  MS  Assay  of  Prasugrel  Active  Metabolite  (R-
138727) and in Plasma 
The concentration of Prasugrel active metabolite (R-138727) 
in  plasma  was  determined  using  LC-MS  /  MS  method. 
Rilpivirine was used as the internal standard. The method has 
already  been  validated  in  terms  of  selectivity,  sensitivity, 
linearity, accuracy and precision, recovery, stability, and also 
has  been  verified  just  before  being  used  in  study.  The 
standard calibration curves for Prasugrel were ranged from 1-
500.19 ng / mL. The best linear fit and least-squares residual 
for the calibration curve were achieved with 1 / x 2 weighing 
factor. The analytical separation (97:3), pumped at 0.6 mL / 
min for 3.0 minutes run time. The column temperature was 
maintained at 40°C. Briefly, a 250 μL of human plasma in 
microtube  was  added  with  20  μL  of  internal  standard  (10 
ppm). After  mixing, 250 μL  of acetonitrile was added  and 
vortex mixed for 30 seconds. The mixture was centrifuged at 
3000 rpm for 10 minutes. A volume of 5 μL supernatant was 
injected into LC-MS / MS system. 
 
Pharmacokinetic and Statistical Analysis 
The  bioequivalence  was  determined  using  the  primary 
parameters,  AUC0-t,  AUC0-∞,  Cmax.  Cmax  and  tmax were 
obtained directly by inspection of the individual drug plasma 
concentration time data, and were used as measures of rate of 
absorption. AUC0-t was calculated using the trapezoidal rule. Sahu Nimain Charan et al. Int. Res. J. Pharm. 2013, 4 (8) 
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The  elimination  rate  constant  (Kel)  was  calculated  by  the 
technique of least-squares regression from the data of the last 
3-5  points  of  each  plasma  concentration  data  curve.  The 
AUC0-∞ values were determined by adding the quotient of Ct 
and the appropriate Kel to the corresponding AUC0-t, that is: 
 
AUC0-∞ = AUC0-t + Ct / Kel 
 
The apparent elimination half-life (t½) of Prasugrel in plasma 
was calculated by using the following equation: 
 
t½= (ln 2) / Kel 
 
For  the  parameters  of  AUC0-t,  AUC0-∞ and  Cmax a 
multiplicative model was assumed, and analysis of variance 
(ANOVA) was applied using the respective in-transformed 
data. For estimation of  bioequivalence the 90  % CI of the 
geometric mean ratio test / reference (T/R) for AUC0-t, AUC0-
∞ and Cmax were calculated assuming a multiplicative model. 
The accepted bioequivalence range for these parameters was 
80-125  %.  The  statistical  analyses  of  least  square  means 
(LSM) of test and reference product were  performed using 
WinNonlin  Pro
®  Software  version  5.3(Phargist,  USA)  or 
above. 
 
RESULTS 
Both  Prasugrel  formulations  were  well-tolerated  at  the 
administered dose and no significant adverse clinical events 
were observed. There were no serious adverse events. A total 
of 20 subjects participated in this study and all the subjects 
were available for pharmacokinetic evaluation. The Prasugrel 
concentration  vs.  time  profiles  of  20  subjects  for  both 
formulations  is  shown  in  Supplementary Figure  1.  The 
pharmacokinetic  parameters  that  are  used  to  assess  the 
bioequivalence of the test  formulation  versus the reference 
were  AUC0-t,  AUC0-∞ for  the  extent  of  the  absorption  and 
Cmax and tmax for the rate of absorption. Descriptive statistics 
of  the  pharmacokinetic  parameter  for  Prasugrel  test  and 
reference  are  summarized  in Table  3 where  the  geometric 
mean values and the range for the AUC0-t, AUC0-∞, Cmax and 
t½ values  obtained  for  each  formulation  are  shown.  The 
pharmacokinetic  characteristic  tmax was  presented  as  mean 
values.  The  mean  obtained  values  for  test  and  reference 
formulations  for test and reference  formulations in case  of 
active metabolite are shown in the Table 4. The ratio analysis 
of  untransformed  data  and  difference  of  log  transformed 
primary pharmacokinetic parameters [Cmax, AUC (0-t) and 
AUC (0-inf)]  for Prasugrel (active  metabolite)  for test  and 
reference  formulation  were  calculated.  Arithmetic  least 
square mean (LSM) ratio was found to be 99.56, 100.5, and 
100.03 for Cmax, AUC  (0-t) and AUC  (0-inf) respectively.  The 
geometric  least  square  mean  (LSM)  ratio  was  found  to  be 
96.80, 100.39 and 100.25 for Cmax, AUC (0-t) and AUC (0-inf) 
respectively. 90 % confidence intervals Cmax, AUC  (0-t) and 
AUC (0-inf) were 90.80-103.20, 95.82-105.18, and 96.00-104.6 
for log-transformed data respectively.                         .
 
Table 1: Summary Data for the Subjects Enrolled in the Study (20 + 2 subjects) 
 
  Age (year)  Weight(kg)  Height (cm)  BMI (kg / m
2) 
Mean  30.50  165.93  59.03  21.37 
SD  6.62  7.01  7.69  2.06 
CV %  21.70  4.23  13.02  9.62 
Median  32.00  165.75  56.65  21.45 
Minimum  20.00  153.50  50.00  18.20 
Maximum  41.00  178.50  73.80  24.80 
 
Table 2: Parameters of Active Metabolite (R-138727) 
 
Parameter  Test Product  Reference Product 
tmax (h)  0.59  0.67 
Cmax  (µg / ml)  7.2857  7.3182 
AUC0-t  (µg.h / ml)  7.8361  7.322 
AUC0-∞  (µg.h / ml)  7.8798  7.8773 
 
Table 3: Summary Statistics of Untransformed Pharmacokinetic Parameters for Prasugrel in 20 Healthy, Human, Adult Subjects 
 
PK Parametrs  Test Product (T)  Reference Product (R) 
Cmax(µg / ml)  150.02  347.16  1526.16  241.88 
AUC0t(µg.hr / ml)  2621.27  674.32  2603.72  643.40 
AUC0-∞(µg.hr / ml)  2731.95  679.44  2720.67  661.96 
t1/2(h)  11.68  4.51  12.01  4.95 
Kel(h
-1)  0.07  0.03  0.07  0.03 
  Median 
Tmax(h)  0.59  0.67 
 
Table 4: Summary Statistics of Log-Transfromed Pharmacokinetic Parameters for Prasugrel in 18 Healthy Human Adult Subjects 
 
Product / Statistics  Cmax(µg / ml)  AUC0-t (µg.h / ml)  AUC0-∞ (µg.h / ml) 
Product T Geometric mean  1429.2722  2530.2079  2643.2997 
N  20  20  20 
Product R Geometric mean  1507.4504  2520.4386  2636.6607 
N  20  20  20 
Anti-log of least square mean       
T  7.2857  7.8361  7.8798 
R  7.3812  7.8322  7.8773 
Geometric mean ratio of t / r (%)  96.80  100.39  100.25 
90 % confidence interval  90.80-103.20  95.82-105.18  96.00-104.69 
Power (%)  0.998  1.0000  1.0000 
Intra-subject CV (%)  11.70  8.50  7.91 Sahu Nimain Charan et al. Int. Res. J. Pharm. 2013, 4 (8) 
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The results of the bioequivalence analysis for prasugrel are 
given in the Table 2 and 3. The intra-subject  variability of 
Prasugrel in the AUC0-t, AUC0-∞, Cmax, and t½ estimates from 
the  coefficient  of  variables  as  determined  by  ANOVA.  As 
shown in Table IV, 90 % confidence intervals (CI) of AUCt, 
AUC0-∞,  Cmax,  and  t½ log-transformed  individual  ratios  of 
Prasugrel were included into the range of bioequivalence, i.e. 
80-125  %  when  analyzed  by  parametric  statistics.
8  In  the 
same  way,  individual  tmax difference  was  not  statistically 
different  between  the  two  formulations.  The  mean  ratio  of 
AUC0-t/AUC0-∞ for  all  individuals  and  for  both  products 
indicate  an  adequate  sampling  time  since  the  extrapolated 
portion of the total AUC is less than 20 %. The results for 
t½ in the present study (11.68 ± 4.51 h for test product and 
12.01 ± 4.95 h for reference product) were consistent with the 
results reported in the literatures. 
 
DISCUSSION 
During  the  past  quarter  of  a  century,  huge  advances  have 
been made in our understanding of the Pathophysiology of 
ACS,  and  these  advances  have  been  accompanied  by 
important breakthroughs in the management of this condition. 
Platelets play a crucial role in ACS, and newer anti platelet 
drugs continue to be developed with the goal of maximizing 
the  reduction  in  atherothrombotic  events  while  minimizing 
bleeding complications. Prasugrel is one of such drugs, which 
is  an  anti  platelet  agent  whose  mechanism  of  action  is  to 
irreversibly  antagonizing  the  P2Y12  class  of  platelet  ADP 
receptor.  The  present  study  indicates  clinical  safety  of 
prasugrel  and  its  bioequivalence  with  effient
®  tablet.  The 
study also indicates that prasugrel tablet is well-tolerated in 
the healthy human volunteers. 
 
CONCLUSION 
With  the  present  results  available,  it  may  be  regarded  as 
prasugrel  tablet  is  safe  and  well-tolerated  in  subjects  with 
acute  coronary  syndrome.  The  application  of  either 
parametric or nonparametric statistics reveals the presence of 
bioequivalence between Effient
® tablet produced by Eli Lilly 
and  Company  and  Prasugrel  tablet  produced  by  Panacea 
biotech for the rate and extent of absorption. Thus, it can be 
assumed  that  the  two  formulations  are  therapeutically 
equivalent and therefore interchangeable. 
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